Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 198-215

  Blanz, Judith ^a   Saftig, Paul ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Gaucher disease; LIMP 2; Parkinson's Disease; synucleinopathies; synuclein; glucocerebrosidase

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE;

AUTOPHAGY; CELL DEATH; CELL LOSS; CELL MEMBRANE; DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINE RELEASE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GBA1 GENE; GENE; GENE FUNCTION; GENE MUTATION; LYSOSOME; NERVE CELL; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; SYNUCLEINOPATHIES;

EID: 84991254228     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13517     Document Type: Review

References (238)

1. Aflaki E., Stubblefield B. K., Maniwang E. et al. (2014) Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci. Transl. Med. 6, 240ra273.
2. Ahmed I., Liang Y., Schools S., Dawson V. L., Dawson T. M. and Savitt J. M. (2012) Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J. Neurosci. 32, 16503–16509.
3. Akiyama H., Sasaki N., Hanazawa S., Gotoh M., Kobayashi S., Hirabayashi Y. and Murakami-Murofushi K. (2011) Novel sterol glucosyltransferase in the animal tissue and cultured cells: evidence that glucosylceramide as glucose donor. Biochim. Biophys. Acta 1811, 314–322.
4. Akiyama H., Kobayashi S., Hirabayashi Y. and Murakami-Murofushi K. (2013) Cholesterol glucosylation is catalyzed by transglucosylation reaction of beta-glucosidase 1. Biochem. Biophys. Res. Commun. 441, 838–843.
5. Alattia J. R., Shaw J. E., Yip C. M. and Prive G. G. (2006) Direct visualization of saposin remodelling of lipid bilayers. J. Mol. Biol. 362, 943–953.
6. Alattia J. R., Shaw J. E., Yip C. M. and Prive G. G. (2007) Molecular imaging of membrane interfaces reveals mode of beta-glucosidase activation by saposin C. Proc. Natl Acad. Sci. USA 104, 17394–17399.
7. Alcalay R. N., Dinur T., Quinn T. et al. (2014) Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 71, 752–757.
8. Alvarez-Erviti L., Rodriguez-Oroz M. C., Cooper J. M., Caballero C., Ferrer I., Obeso J. A. and Schapira A. H. (2010) Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 67, 1464–1472.
9. Alvarez-Erviti L., Seow Y., Schapira A. H., Rodriguez-Oroz M. C., Obeso J. A. and Cooper J. M. (2013) Influence of microRNA deregulation on chaperone-mediated autophagy and alpha-synuclein pathology in Parkinson's disease. Cell Death Dis. 4, e545.
10. Ambrosi G., Ghezzi C., Zangaglia R., Levandis G., Pacchetti C. and Blandini F. (2015) Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. Neurobiol. Dis. 82, 235–242.
11. Anglade P., Vyas S., Javoy-Agid F. et al. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25–31.
12. Aureli M., Masilamani A. P., Illuzzi G., Loberto N., Scandroglio F., Prinetti A., Chigorno V. and Sonnino S. (2009) Activity of plasma membrane beta-galactosidase and beta-glucosidase. FEBS Lett. 583, 2469–2473.
13. Aureli M., Bassi R., Loberto N. et al. (2012) Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts. J. Inherit. Metab. Dis. 35, 1081–1091.
14. Awad O., Sarkar C., Panicker L. M., Miller D., Zeng X., Sgambato J. A., Lipinski M. M. and Feldman R. A. (2015) Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum. Mol. Genet. 24, 5775–5788.
15. Bae E. J., Yang N. Y., Song M. et al. (2014) Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat. Commun. 5, 4755.
16. Bae E. J., Yang N. Y., Lee C., Lee H. J., Kim S., Sardi S. P. and Lee S. J. (2015) Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp. Mol. Med. 47, e153.
17. Baek J. H., Whitfield D., Howlett D., Francis P., Bereczki E., Ballard C., Hortobagyi T., Attems J. and Aarsland D. (2015) Unfolded protein response is activated in Lewy body dementias. Neuropathol. Appl. Neurobiol.
18. Ballabio A. and Gieselmann V. (2009) Lysosomal disorders: from storage to cellular damage. Biochim. Biophys. Acta 1793, 684–696.
19. Bendikov-Bar I. and Horowitz M. (2012) Gaucher disease paradigm: from ERAD to comorbidity. Hum. Mutat. 33, 1398–1407.
20. Bendikov-Bar I., Ron I., Filocamo M. and Horowitz M. (2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol. Dis. 46, 4–10.
21. Bendikov-Bar I., Maor G., Filocamo M. and Horowitz M. (2013) Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141–145.
22. Bendikov-Bar I., Rapaport D., Larisch S. and Horowitz M. (2014) Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS. Orphanet J. Rare. Dis. 9, 86.
23. Benito J. M., Garcia Fernandez J. M. and Ortiz Mellet C. (2011) Pharmacological chaperone therapy for Gaucher disease: a patent review. Expert Opin. Ther. Pat. 21, 885–903.
24. Berkovic S. F., Dibbens L. M., Oshlack A. et al. (2008) Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am. J. Hum. Genet. 82, 673–684.
25. Beutler E. (1992) Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256, 794–799.
26. Beutler E., Kuhl W., Trinidad F., Teplitz R. and Nadler H. (1971) Beta-glucosidase activity in fibroblasts from homozygotes and heterozygotes for Gaucher's disease. Am. J. Hum. Genet. 23, 62–66.
27. Blanz J., Zunke F., Markmann S., Damme M., Braulke T., Saftig P. and Schwake M. (2015) Mannose 6-phosphate-independent Lysosomal Sorting of LIMP-2. Traffic 16(10), 1127–1136.
28. Bonifati V. (2014) Genetics of Parkinson's disease–state of the art, 2013. Parkinsonism Relat. Disord. 20(Suppl 1), S23–S28.
29. Boot R. G., Verhoek M., Donker-Koopman W., Strijland A., van Marle J., Overkleeft H. S., Wennekes T. and Aerts J. M. (2007) Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J. Biol. Chem. 282, 1305–1312.
30. Bove J., Martinez-Vicente M. and Vila M. (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 12, 437–452.
31. Brady R. O., Kanfer J. N., Mock M. B. and Fredrickson D. S. (1966) The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. Proc. Natl Acad. Sci. USA 55, 366–369.
32. Bras J., Guerreiro R., Darwent L. et al. (2014) Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum. Mol. Genet. 23, 6139–6146.
33. Brockmann K. and Berg D. (2014) The significance of GBA for Parkinson's disease. J. Inherit. Metab. Dis. 37, 643–648.
34. Bultron G., Kacena K., Pearson D., Boxer M., Yang R., Sathe S., Pastores G. and Mistry P. K. (2010) The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis. 33, 167–173.
35. Burke D. G., Rahim A. A., Waddington S. N., Karlsson S., Enquist I., Bhatia K., Mehta A., Vellodi A. and Heales S. (2013) Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes. J. Inherit. Metab. Dis. 36, 869–872.
36. Cao S. S. and Kaufman R. J. (2012) Unfolded protein response. Curr. Biol. 22, R622–R626.
37. Chalat M., Menon I., Turan Z. and Menon A. K. (2012) Reconstitution of glucosylceramide flip-flop across endoplasmic reticulum: implications for mechanism of glycosphingolipid biosynthesis. J. Biol. Chem. 287, 15523–15532.
38. Chaves J., Beirao I., Balreira A., Gaspar P., Caiola D., Sa-Miranda M. C. and Lima J. L. (2011) Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency: clinical report of two siblings. Seizure 20, 738–740.
39. Cherin P., Rose C., de Roux-Serratrice C. et al. (2010) The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). J. Inherit. Metab. Dis. 33, 331–338.
40. Chiang H. L. and Dice J. F. (1988) Peptide sequences that target proteins for enhanced degradation during serum withdrawal. J. Biol. Chem. 263, 6797–6805.
41. Chiang H. L., Terlecky S. R., Plant C. P. and Dice J. F. (1989) A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 246, 382–385.
42. Chiasserni D., Paciotti S., Eusebi P. et al. (2015) Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 10, 15.
43. Christomanou H., Aignesberger A. and Linke R. P. (1986) Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Bio. Chem. Hoppe-Seyler 367, 879–890.
44. Chu Y., Dodiya H., Aebischer P., Olanow C. W. and Kordower J. H. (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385–398.
45. Clark L. N. (2009) Variation on a theme: identifying sequence variation in disease genes and defining pathogenicity. Neurology 72, 1882–1883.
46. Cooper A. A., Gitler A. D., Cashikar A. et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313, 324–328.
47. Cox T. M. (2001) Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J. Inherit. Metab. Dis. 24 Suppl 2, 106–121; discussion 187–108.
48. Cuervo A. M. (2010) Chaperone-mediated autophagy: selectivity pays off. Trends Endocrinol. Metab. 21, 142–150.
49. Cuervo A. M. and Dice J. F. (1996) A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273, 501–503.
50. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295.
51. Danes B. S. and Bearn A. G. (1968) Gaucher's disease: a genetic disease detected in skin fibroblast cultures. Science 161, 1347–1348.
52. D'Angelo G., Polishchuk E., Di Tullio G. et al. (2007) Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449, 62–67.
53. Decressac M., Mattsson B., Weikop P., Lundblad M., Jakobsson J. and Bjorklund A. (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc. Natl Acad. Sci. USA 110, E1817–E1826.
54. Dehay B., Bove J., Rodriguez-Muela N., Perier C., Recasens A., Boya P. and Vila M. (2010) Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535–12544.
55. Devine E. A., Smith M., Arredondo-Vega F. X., Shafit-Zagardo B. and Desnick R. J. (1982) Chromosomal localization of the gene for Gaucher disease. Prog. Clin. Biol. Res. 95, 511–534.
56. Devine M. J., Gwinn K., Singleton A. and Hardy J. (2011) Parkinson's disease and alpha-synuclein expression. Mov. Disord. 26, 2160–2168.
57. Dibbens L. M., Michelucci R., Gambardella A. et al. (2009) SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure. Ann. Neurol. 66, 532–536.
58. Do C. B., Tung J. Y., Dorfman E. et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet. 7, e1002141.
59. Du T. T., Wang L., Duan C. L., Lu L. L., Zhang J. L., Gao G., Qiu X. B., Wang X. M. and Yang H. (2015) GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy 11, 1803–1820.
60. Elleder M. (2006) Glucosylceramide transfer from lysosomes–the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J. Inherit. Metab. Dis. 29, 707–715.
61. Enquist I. B., Lo Bianco C., Ooka A. et al. (2007) Murine models of acute neuronopathic Gaucher disease. Proc. Natl Acad. Sci. USA 104, 17483–17488.
62. Fan J. Q. and Ishii S. (2007) Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J. 274, 4962–4971.
63. Farfel-Becker T., Vitner E., Dekel H., Leshem N., Enquist I. B., Karlsson S. and Futerman A. H. (2009) No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum. Mol. Genet. 18, 1482–1488.
64. Farfel-Becker T., Vitner E. B., Kelly S. L., Bame J. R., Duan J., Shinder V., Merrill A. H. Jr, Dobrenis K. and Futerman A. H. (2014) Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 23, 843–854.
65. Farrer M. J. (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306–318.
66. Ferraz M. J., Kallemeijn W. W., Mirzaian M. et al. (2014) Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim. Biophys. Acta 1841, 811–825.
67. Friedman L. G., Lachenmayer M. L., Wang J., He L., Poulose S. M., Komatsu M., Holstein G. R. and Yue Z. (2012) Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. J. Neurosci. 32, 7585–7593.
68. Furst W. and Sandhoff K. (1992) Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta 1126, 1–16.
69. Gamp A. C., Tanaka Y., Lullmann-Rauch R. et al. (2003) LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. Hum. Mol. Genet. 12, 631–646.
70. Gan-Or Z., Giladi N. and Orr-Urtreger A. (2009) Differential phenotype in Parkinson's disease patients with severe versus mild GBA mutations. Brain 132, e125.
71. Gan-Or Z., Ozelius L. J., Bar-Shira A. et al. (2013) The p. L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 80, 1606–1610.
72. Gan-Or Z., Dion P. A. and Rouleau G. A. (2015) Genetic perspective on the role of the Autophagy-Lysosome Pathway in Parkinson disease. Autophagy, 11(9), 1443–1457.
73. Gegg M. E., Burke D., Heales S. J., Cooper J. M., Hardy J., Wood N. W. and Schapira A. H. (2012) Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455–463.
74. Gegg M. E., Sweet L., Wang B. H., Shihabuddin L. S., Sardi S. P. and Schapira A. H. (2015) No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 30, 1085–1089.
75. Giasson B. I., Duda J. E., Quinn S. M., Zhang B., Trojanowski J. Q. and Lee V. M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521–533.
76. Gieselmann V. (1995) Lysosomal storage diseases. Biochim. Biophys. Acta 1270, 103–136.
77. Ginns E. I., Choudary P. V., Tsuji S., Martin B., Stubblefield B., Sawyer J., Hozier J. and Barranger J. A. (1985) Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease. Proc. Natl Acad. Sci. USA 82, 7101–7105.
78. Gitler A. D., Chesi A., Geddie M. L. et al. (2009) Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308–315.
79. Goker-Alpan O., Schiffmann R., Park J. K., Stubblefield B. K., Tayebi N. and Sidransky E. (2003) Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J. Pediatr. 143, 273–276.
80. Goker-Alpan O., Schiffmann R., LaMarca M. E., Nussbaum R. L., McInerney-Leo A. and Sidransky E. (2004) Parkinsonism among Gaucher disease carriers. J. Med. Genet. 41, 937–940.
81. Goker-Alpan O., Giasson B. I., Eblan M. J., Nguyen J., Hurtig H. I., Lee V. M., Trojanowski J. Q. and Sidransky E. (2006) Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67, 908–910.
82. Goker-Alpan O., Stubblefield B. K., Giasson B. I. and Sidransky E. (2010) Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 120, 641–649.
83. Gonzalez-Carmona M. A., Sandhoff R., Tacke F. et al. (2012) Beta-glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration. Liver Int. 32, 1354–1362.
84. Grabowski G. A., Gatt S. and Horowitz M. (1990) Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease. Crit. Rev. Biochem. Mol. Biol. 25, 385–414.
85. Gruschus J. M., Jiang Z., Yap T. L., Hill S. A., Grishaev A., Piszczek G., Sidransky E. and Lee J. C. (2015) Dissociation of glucocerebrosidase dimer in solution by its co-factor, saposin C. Biochem. Biophys. Res. Commun. 457, 561–566.
86. Halperin A., Elstein D. and Zimran A. (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis. 36, 426–428.
87. Halter D., Neumann S., van Dijk S. M. et al. (2007) Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J. Cell Biol. 179, 101–115.
88. Hammer M. B., Eleuch-Fayache G., Schottlaender L. V. et al. (2013) Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am. J. Hum. Genet. 92, 245–251.
89. Hely M. A., Reid W. G., Adena M. A., Halliday G. M. and Morris J. G. (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837–844.
90. Hernandez D., Torres C. A., Setlik W. et al. (2012) Regulation of presynaptic neurotransmission by macroautophagy. Neuron 74, 277–284.
91. Herrlin K. M. and Hillborg P. O. (1962) Neurological signs in a juvenile form of Gaucher's disease. Acta Paediatr. 51, 137–154.
92. Hirabayashi Y. (2012) A world of sphingolipids and glycolipids in the brain–novel functions of simple lipids modified with glucose. Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci. 88, 129–143.
93. Ho M. W. and O'Brien J. S. (1971) Gaucher's disease: deficiency of ‘acid’ -glucosidase and reconstitution of enzyme activity in vitro. Proc. Natl Acad. Sci. USA 68, 2810–2813.
94. Hong C. M., Ohashi T., Yu X. J., Weiler S. and Barranger J. A. (1990) Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol. 9, 233–241.
95. Hopfner F., Schulte E. C., Mollenhauer B. et al. (2013) The role of SCARB2 as susceptibility factor in Parkinson's disease. Mov. Disord. 28, 538–540.
96. Horowitz M., Wilder S., Horowitz Z., Reiner O., Gelbart T. and Beutler E. (1989) The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 4, 87–96.
97. Horowitz M., Tzuri G., Eyal N., Berebi A., Kolodny E. H., Brady R. O., Barton N. W., Abrahamov A. and Zimran A. (1993) Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am. J. Hum. Genet. 53, 921–930.
98. Hruska K. S., LaMarca M. E., Scott C. R. and Sidransky E. (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567–583.
99. Imai Y., Soda M. and Takahashi R. (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275, 35661–35664.
100. Jmoudiak M. and Futerman A. H. (2005) Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 129, 178–188.
101. Kabuta T. and Wada K. (2008) Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy 4, 827–829.
102. Kemeny S., Dery D., Loboda Y., Rovner M., Lev T., Zuri D., Finberg J. P. and Larisch S. (2012) Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein. PLoS ONE 7, e38837.
103. Kishimoto Y., Hiraiwa M. and O'Brien J. S. (1992) Saposins: structure, function, distribution, and molecular genetics. J. Lipid Res. 33, 1255–1267.
104. Komatsu M., Waguri S., Ueno T. et al. (2005) Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 169, 425–434.
105. Komatsu M., Waguri S., Chiba T. et al. (2006) Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441, 880–884.
106. Kong S. M., Chan B. K., Park J. S. et al. (2014) Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes alpha-Synuclein externalization via exosomes. Hum. Mol. Genet. 23, 2816–2833.
107. Korkotian E., Schwarz A., Pelled D., Schwarzmann G., Segal M. and Futerman A. H. (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274, 21673–21678.
108. Körschen H. G., Yildiz Y., Raju D. N., Schonauer S., Bonigk W., Jansen V., Kremmer E., Kaupp U. B. and Wachten D. (2013) The non-lysosomal beta-glucosidase GBA2 is a non-integral membrane-associated protein at the endoplasmic reticulum (ER) and Golgi. J. Biol. Chem. 288, 3381–3393.
109. Kurzawa-Akanbi M., Hanson P. S., Blain P. G., Lett D. J., McKeith I. G., Chinnery P. F. and Morris C. M. (2012) Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J. Neurochem. 123, 298–309.
110. Lannert H., Bunning C., Jeckel D. and Wieland F. T. (1994) Lactosylceramide is synthesized in the lumen of the Golgi apparatus. FEBS Lett. 342, 91–96.
111. Lannert H., Gorgas K., Meissner I., Wieland F. T. and Jeckel D. (1998) Functional organization of the Golgi apparatus in glycosphingolipid biosynthesis. Lactosylceramide and subsequent glycosphingolipids are formed in the lumen of the late Golgi. J. Biol. Chem. 273, 2939–2946.
112. Latham T. E., Theophilus B. D., Grabowski G. A. and Smith F. I. (1991) Heterogeneity of mutations in the acid beta-glucosidase gene of Gaucher disease patients. DNA Cell Biol. 10, 15–21.
113. Lee H. J., Bae E. J. and Lee S. J. (2014) Extracellular alpha–synuclein-a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98.
114. Lees A. J., Hardy J. and Revesz T. (2009) Parkinson's disease. Lancet 373, 2055–2066.
115. Legler G. and Bieberich E. (1988) Active site directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconduritol B epoxide and bromoconduritol F. Arch. Biochem. Biophys. 260, 437–442.
116. Lesage S., Anheim M., Condroyer C. et al. (2011) Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum. Mol. Genet. 20, 202–210.
117. Li G., Yang H., Zhu D., Huang H., Liu G. and Lun P. (2014) Targeted suppression of chaperone-mediated autophagy by miR-320a promotes alpha-synuclein aggregation. Int. J. Mol. Sci. 15, 15845–15857.
118. Lloyd-Evans E., Pelled D., Riebeling C., Bodennec J., de-Morgan A., Waller H., Schiffmann R. and Futerman A. H. (2003) Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem. 278, 23594–23599.
119. Lorenz H., Hailey D. W. and Lippincott-Schwartz J. (2006) Fluorescence protease protection of GFP chimeras to reveal protein topology and subcellular localization. Nat. Methods 3, 205–210.
120. Mak S. K., McCormack A. L., Manning-Bog A. B., Cuervo A. M. and Di Monte D. A. (2010) Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 285, 13621–13629.
121. Malkus K. A. and Ischiropoulos H. (2012) Regional deficiencies in chaperone-mediated autophagy underlie alpha-synuclein aggregation and neurodegeneration. Neurobiol. Dis. 46, 732–744.
122. Manning-Bog A. B., Schule B. and Langston J. W. (2009) Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127–1132.
123. Maor G., Rencus-Lazar S., Filocamo M., Steller H., Segal D. and Horowitz M. (2013) Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J. Rare. Dis. 8, 140.
124. Marques A. R., Aten J., Ottenhoff R. et al. (2015) Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice. PLoS ONE 10, e0135889.
125. Martinez-Vicente M., Talloczy Z., Kaushik S. et al. (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118, 777–788.
126. Matern H., Heinemann H., Legler G. and Matern S. (1997) Purification and characterization of a microsomal bile acid beta-glucosidase from human liver. J. Biol. Chem. 272, 11261–11267.
127. Matern H., Boermans H., Lottspeich F. and Matern S. (2001) Molecular cloning and expression of human bile acid beta-glucosidase. J. Biol. Chem. 276, 37929–37933.
128. Mazzulli J. R., Xu Y. H., Sun Y., Knight A. L., McLean P. J., Caldwell G. A., Sidransky E., Grabowski G. A. and Krainc D. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37–52.
129. McKeith I. G., Dickson D. W., Lowe J. et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863–1872.
130. McKeran R. O., Bradbury P., Taylor D. and Stern G. (1985) Neurological involvement in type 1 (adult) Gaucher's disease. J. Neurol. Neurosurg. Psychiatry 48, 172–175.
131. McNeill A., Magalhaes J., Shen C. et al. (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137, 1481–1495.
132. Michelakakis H., Xiromerisiou G., Dardiotis E. et al. (2012) Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. Mov. Disord. 27, 400–405.
133. Miller J. D., McCluer R. and Kanfer J. N. (1973) Gaucher's disease: neurologic disorder in adult siblings. Ann. Intern. Med. 78, 883–887.
134. Mistry P. K., Liu J., Sun L. et al. (2014) Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc. Natl Acad. Sci. USA 111, 4934–4939.
135. Mitsui J., Mizuta I., Toyoda A. et al. (2009) Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol. 66, 571–576.
136. Mizukami H., Mi Y., Wada R. et al. (2002) Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J. Clin. Investig. 109, 1215–1221.
137. Moore D. J., West A. B., Dawson V. L. and Dawson T. M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57–87.
138. Murphy K. E., Gysbers A. M., Abbott S. K., Tayebi N., Kim W. S., Sidransky E., Cooper A., Garner B. and Halliday G. M. (2014) Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 137, 834–848.
139. Najim al-Din A. S., Wriekat A., Mubaidin A., Dasouki M. and Hiari M. (1994) Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 89, 347–352.
140. Nalls M. A., Duran R., Lopez G. et al. (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 70, 727–735.
141. Neculai D., Schwake M., Ravichandran M., Zunke F., Collins R. F., Peters J., Neculai M., Plumb J., Loppnau P., Pizarro J. C., Seitova A., Trimble W. S., Saftig P., Grinstein S. and Dhe-Paganon S. (2013) Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nat. 504, 172–176.
142. Neil J. F., Glew R. H. and Peters S. P. (1979) Familial psychosis and diverse neurologic abnormalities in adult-onset Gaucher's disease. Arch. Neurol. 36, 95–99.
143. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B. and Zimran A. (1996) Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 89, 691–694.
144. Neumann J., Bras J., Deas E. et al. (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783–1794.
145. Nichols W. C., Pankratz N., Marek D. K. et al. (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72, 310–316.
146. Nilsson O. and Svennerholm L. (1982) Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J. Neurochem. 39, 709–718.
147. Nishimura K. and Yamakawa T. (1968) Isolation of cerebroside containing glucose (Glucosyl ceramide) and its possible significance in ganglioside synthesis. Lipids 3, 262–266.
148. Ohsumi Y. (2001) Molecular dissection of autophagy: two ubiquitin-like systems. Nat. Rev. Mol. Cell Biol. 2, 211–216.
149. Orenstein S. J., Kuo S. H., Tasset I. et al. (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394–406.
150. Orvisky E., Park J. K., LaMarca M. E., Ginns E. I., Martin B. M., Tayebi N. and Sidransky E. (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 76, 262–270.
151. Owada M., Sakiyama T. and Kitagawa T. (1977) Neuropathic Gaucher's disease with normal 4-methylumbelliferyl-beta-glucosidase activity in the liver. Pediatr. Res. 11, 641–646.
152. Palmieri M., Impey S., Kang H., di Ronza A., Pelz C., Sardiello M. and Ballabio A. (2011) Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 20, 3852–3866.
153. Pang S., Chen D., Zhang A., Qin X. and Yan B. (2012) Genetic analysis of the LAMP-2 gene promoter in patients with sporadic Parkinson's disease. Neurosci. Lett. 526, 63–67.
154. Park J. S., Koentjoro B., Veivers D., Mackay-Sim A. and Sue C. M. (2014) Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. 23, 2802–2815.
155. Pastores G. M. (2010) Neuropathic gaucher disease. Wien. Med. Wochenschr. 160, 605–608.
156. Patnaik S., Zheng W., Choi J. H. et al. (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J. Med. Chem. 55, 5734–5748.
157. Pchelina S. N., Nuzhnyi E. P., Emelyanov A. K., Boukina T. M., Usenko T. S., Nikolaev M. A., Salogub G. N., Yakimovskii A. F. and Zakharova E. Y. (2014) Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci. Lett. 583, 188–193.
158. Pelled D., Trajkovic-Bodennec S., Lloyd-Evans E., Sidransky E., Schiffmann R. and Futerman A. H. (2005) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 18, 83–88.
159. Pentchev P. G., Gal A. E., Booth A. D., Omodeo-Sale F., Fouks J., Neumeyer B. A., Quirk J. M., Dawson G. and Brady R. O. (1980) A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. Biochim. Biophys. Acta 619, 669–679.
160. Perrett R. M., Alexopoulou Z. and Tofaris G. K. (2015) The endosomal pathway in Parkinson's disease. Mol. Cell Neurosci. 66, 21–28.
161. Platt F. M., Boland B. and van der Spoel A. C. (2012) The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol. 199, 723–734.
162. Polymeropoulos M. H., Higgins J. J., Golbe L. I. et al. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 1197–1199.
163. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
164. Qi X. and Grabowski G. A. (1998) Acid beta-glucosidase: intrinsic fluorescence and conformational changes induced by phospholipids and saposin C. Biochemistry 37, 11544–11554.
165. Qi X. and Grabowski G. A. (2001) Molecular and cell biology of acid beta-glucosidase and prosaposin. Prog. Nucleic Acid Res. Mol. Biol. 66, 203–239.
166. Ramirez A., Heimbach A., Grundemann J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184–1191.
167. Ramonet D., Podhajska A., Stafa K. et al. (2012) PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet. 21, 1725–1743.
168. Reczek D., Schwake M., Schroder J. et al. (2007) LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131, 770–783.
169. Richter F., Fleming S. M., Watson M. et al. (2014) A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics 11, 840–856.
170. Ron I. and Horowitz M. (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387–2398.
171. Ron I. and Horowitz M. (2008) Intracellular cholesterol modifies the ERAD of glucocerebrosidase in Gaucher disease patients. Mol. Genet. Metab. 93, 426–436.
172. Ron I., Rapaport D. and Horowitz M. (2010) Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Hum. Mol. Genet. 19, 3771–3781.
173. Rothaug M., Zunke F., Mazzulli J. R. et al. (2014) LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance. Proc. Natl Acad. Sci. USA 111, 15573–15578.
174. Rothaug M., Stroobants S., Schweizer M., Peters J., Zunke F., Allerding M., D'Hooge R., Saftig P. and Blanz J. (2015) LAMP-2 deficiency leads to hippocampal dysfunction but normal clearance of neuronal substrates of chaperone-mediated autophagy in a mouse model for Danon disease. Acta. Neuropathol. Commun. 3, 6.
175. Rott R., Szargel R., Shani V., Bisharat S. and Engelender S. (2014) Alpha-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 13, 630–637.
176. Sack G. H. Jr (1980) Clinical diversity in Gaucher's disease. Johns Hopkins Med. J. 146, 166–170.
177. Saftig P. and Klumperman J. (2009) Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623–635.
178. Sardi S. P., Clarke J., Kinnecom C. et al. (2011) CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl Acad. Sci. USA 108, 12101–12106.
179. Sardi S. P., Clarke J., Viel C. et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl Acad. Sci. USA 110, 3537–3542.
180. Sardi S. P., Cheng S. H. and Shihabuddin L. S. (2015) Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle. Prog. Neurobiol. 125, 47–62.
181. Sardiello M., Palmieri M., di Ronza A. et al. (2009) A gene network regulating lysosomal biogenesis and function. Science 325, 473–477.
182. Saunders-Pullman R., Hagenah J., Dhawan V. et al. (2010) Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov. Disord. 25, 1364–1372.
183. Schapira A. H. (2015) Glucocerebrosidase and Parkinson disease: Recent advances. Mol. Cell Neurosci. 66, 37–42.
184. Schnaar R. L., Suzuki A. and Stanley P. (2009) Glycosphingolipids: Essentials of Glycobiology, 2nd edn (Varki A., Cummings R. D. and Esko J. D., et al., eds) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Chapter 10. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1909/
185. Schöndorf D. C., Aureli M., McAllister F. E. et al. (2014) iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5, 4028.
186. Schueler U. H., Kolter T., Kaneski C. R., Blusztajn J. K., Herkenham M., Sandhoff K. and Brady R. O. (2003) Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol. Dis. 14, 595–601.
187. Settembre C., Fraldi A., Medina D. L. and Ballabio A. (2013) Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 14, 283–296.
188. Shachar T., Lo Bianco C., Recchia A., Wiessner C., Raas-Rothschild A. and Futerman A. H. (2011) Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov. Disord. 26, 1593–1604.
189. Shafit-Zagardo B., Devine E. A., Smith M., Arredondo-Vega F. and Desnick R. J. (1981) Assignment of the gene for acid beta-glucosidase to human chromosome 1. Am. J. Hum. Genet. 33, 564–575.
190. Shimura H., Hattori N., Kubo S. et al. (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25, 302–305.
191. Shin J. H., Ko H. S., Kang H., Lee Y., Lee Y. I., Pletinkova O., Troconso J. C., Dawson V. L. and Dawson T. M. (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144, 689–702.
192. Sidransky E., Nalls M. A., Aasly J. O. et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 361, 1651–1661.
193. Siebert M., Sidransky E. and Westbroek W. (2014) Glucocerebrosidase is shaking up the synucleinopathies. Brain 137, 1304–1322.
194. Singleton A. B., Farrer M., Johnson J. et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
195. Sleat D. E., Wiseman J. A., El-Banna M. et al. (2004) Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc. Natl Acad. Sci. USA 101, 5886–5891.
196. Soffer D., Yamanaka T., Wenger D. A., Suzuki K. and Suzuki K. (1980) Central nervous system involvement in adult-onset Gaucher's disease. Acta Neuropathol. 49, 1–6.
197. Song W., Wang F., Savini M., Ake A., di Ronza A., Sardiello M. and Segatori L. (2013) TFEB regulates lysosomal proteostasis. Hum. Mol. Genet. 22, 1994–2009.
198. Sorge J., West C., Westwood B. and Beutler E. (1985) Molecular cloning and nucleotide sequence of human glucocerebrosidase cDNA. Proc. Natl Acad. Sci. USA 82, 7289–7293.
199. Sorli S. C., Colié S., Albinet V. et al. (2013) The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J. 27, 489–498.
200. Stevens D. A., Lee Y., Kang H. C. et al. (2015) Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proc. Natl Acad. Sci. USA 112(37), 11696–11701.
201. Stone D. L., Tayebi N., Orvisky E., Stubblefield B., Madike V. and Sidransky E. (2000) Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum. Mutat. 15, 181–188.
202. Sun Y., Qi X. and Grabowski G. A. (2003) Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation. J. Biol. Chem. 278, 31918–31923.
203. Sun Y., Quinn B., Witte D. P. and Grabowski G. A. (2005) Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J. Lipid Res. 46, 2102–2113.
204. Tamargo R. J., Velayati A., Goldin E. and Sidransky E. (2012) The role of saposin C in Gaucher disease. Mol. Genet. Metab. 106, 257–263.
205. Tanaka Y., Guhde G., Suter A. et al. (2000) Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406, 902–906.
206. Tayebi N., Walker J., Stubblefield B. et al. (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol. Genet. Metab. 79, 104–109.
207. Tofaris G. K. (2012) Lysosome-dependent pathways as a unifying theme in Parkinson's disease. Mov. Disord. 27, 1364–1369.
208. Tsuji S., Choudary P. V., Martin B. M., Stubblefield B. K., Mayor J. A., Barranger J. A. and Ginns E. I. (1987) A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N. Engl. J. Med. 316, 570–575.
209. Tsuji S., Martin B. M., Barranger J. A., Stubblefield B. K., LaMarca M. E. and Ginns E. I. (1988) Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc. Natl Acad. Sci. USA 85, 2349–2352.
210. Tsunemi T. and Krainc D. (2014) Zn(2)(+) dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum. Mol. Genet. 23, 2791–2801.
211. Tsunemi T., Hamada K. and Krainc D. (2014) ATP13A2/PARK9 regulates secretion of exosomes and alpha-synuclein. J. Neurosci. 34, 15281–15287.
212. Tybulewicz V. L., Tremblay M. L., LaMarca M. E. et al. (1992) Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357, 407–410.
213. Tylki-Szymanska A., Czartoryska B., Vanier M. T., Poorthuis B. J., Groener J. A., Lugowska A., Millat G., Vaccaro A. M. and Jurkiewicz E. (2007) Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin. Genet. 72, 538–542.
214. Ueda K., Fukushima H., Masliah E. et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282–11286.
215. Vaccaro A. M., Tatti M., Ciaffoni F., Salvioli R., Barca A. and Scerch C. (1997) Effect of saposins A and C on the enzymatic hydrolysis of liposomal glucosylceramide. J. Biol. Chem. 272, 16862–16867.
216. Valaperta R., Chigorno V., Basso L., Prinetti A., Bresciani R., Preti A., Miyagi T. and Sonnino S. (2006) Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. FASEB J. 20, 1227–1229.
217. Van Bogaert L. and Froehlich A. (1939) Un cas de maladie de Gaucher de l'adulte avec syndrome de Raynaud, pigmentation et rigidite de type extra-pyramidal aux membres inferieurs. Ann. Med. 45, 57–70.
218. Velayati A., DePaolo J., Gupta N. et al. (2011) A mutation in SCARB2 is a modifier in Gaucher disease. Hum. Mutat. 32, 1232–1238.
219. Vogiatzi T., Xilouri M., Vekrellis K. and Stefanis L. (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283, 23542–23556.
220. Webb J. L., Ravikumar B., Atkins J., Skepper J. N. and Rubinsztein D. C. (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009–25013.
221. van Weely S., Brandsma M., Strijland A., Tager J. M. and Aerts J. M. (1993) Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta 1181, 55–62.
222. Wei H., Kim S. J., Zhang Z., Tsai P. C., Wisniewski K. E. and Mukherjee A. B. (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet. 17, 469–477.
223. Weiser T. (2008) Ambroxol: a CNS drug? CNS Neurosci. Ther. 14, 17–24.
224. Wennekes T., van den Berg R. J., Boot R. G., van der Marel G. A., Overkleeft H. S. and Aerts J. M. (2009) Glycosphingolipids–nature, function, and pharmacological modulation. Angew. Chem. 48, 8848–8869.
225. Westbroek W., Gustafson A. M. and Sidransky E. (2011) Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol. Med. 17, 485–493.
226. Wong K., Sidransky E., Verma A. et al. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. Genet. Metab. 82, 192–207.
227. Wu G., Wang X., Feng X. et al. (2011) Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease. Brain Res. 1394, 105–111.
228. Xia R., Sun J. and Threlkeld A. J. (2009) Analysis of interactive effect of stretch reflex and shortening reaction on rigidity in Parkinson's disease. Clin. Neurophysiol. 120, 1400–1407.
229. Xilouri M., Brekk O. R., Landeck N., Pitychoutis P. M., Papasilekas T., Papadopoulou-Daifoti Z., Kirik D. and Stefanis L. (2013) Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration. Brain 136, 2130–2146.
230. Xu Y. H., Quinn B., Witte D. and Grabowski G. A. (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. 163, 2093–2101.
231. Xu Y. H., Sun Y., Ran H., Quinn B., Witte D. and Grabowski G. A. (2011) Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol. Genet. Metab. 102, 436–447.
232. Yap T. L., Gruschus J. M., Velayati A., Westbroek W., Goldin E., Moaven N., Sidransky E. and Lee J. C. (2011) Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286, 28080–28088.
233. Yap T. L., Gruschus J. M., Velayati A., Sidransky E. and Lee J. C. (2013a) Saposin C protects glucocerebrosidase against alpha-synuclein inhibition. Biochemistry 52, 7161–7163.
234. Yap T. L., Velayati A., Sidransky E. and Lee J. C. (2013b) Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab. 108, 56–64.
235. Yap T. L., Jiang Z., Heinrich F., Gruschus J. M., Pfefferkorn C. M., Barros M., Curtis J. E., Sidransky E. and Lee J. C. (2015) Structural features of membrane-bound glucocerebrosidase and alpha-synuclein probed by neutron reflectometry and fluorescence spectroscopy. J. Biol. Chem. 290, 744–754.
236. Yildiz Y., Matern H., Thompson B. et al. (2006) Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J. Clin. Invest. 116, 2985–2994.
237. Zachos C., Blanz J., Saftig P. and Schwake M. (2012) A critical histidine residue within LIMP-2 mediates pH sensitive binding to its ligand beta-glucocerebrosidase. Traffic 13, 1113–1123.
238. Zimran A., Sorge J., Gross E., Kubitz M., West C. and Beutler E. (1989) Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 2, 349–352.